MedTrace Logo

Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.

NCT06982092 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-21

No results posted yet for this study

Summary

The aim of our study is to assess differences in the recovery of muscle function, using diaphragm ultrasonography, after reversal of a rocuronium-induced block, using neostigmine versus sugammadex

Conditions

  • Perioperative Diaphragmatic Function

Interventions

DRUG

sugammadex

: patients will receive the reversal drug according to the group to which they had been randomised. in the Sugammadex Group will receive 2 mg/kg sugammadex.

DRUG

Neostigmine

Patients in the NEO Group will receive 50 mic/kg neostigmine and .01-.02 mg/kg atropine

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Mostafa Hamed Mahmoud, M.B.B.CH · Anesthesia resident Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-26
Primary Completion
2025-01-15
Completion
2025-01-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06982092 on ClinicalTrials.gov